<DOC>
	<DOC>NCT00697788</DOC>
	<brief_summary>Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.</brief_summary>
	<brief_title>Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients</brief_title>
	<detailed_description>This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine bolus/infusions in acutely burned pediatric patients. The study entails a bolus of dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters including EKG, heart rate, oxygen saturation, blood pressure, are recorded.</detailed_description>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>pediatric patient &gt;25% total body surface area (tbsa) burn and &lt; 90% tbsa opioid requirements &gt; 0.1 mg/kg/hour of morphine (or equivalent) midazolam requirement &gt; 0.1 mg/kg/hour treatment team determined that patient should be started on dexmedetomidine hemodynamically unstable patients (epinephrine &gt; 1.0 ug/kg/min, levophed &gt; 0.75 ug/kg/min, dopamine &gt; 10 ug/kg/min) pregnant patients patients with history of heart block patients with congenital heart disease patients with significant hepatic dysfunction patients with urine output &lt; 0.5 ml/kg/hour [averaged] over past 24 hours</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pediatric</keyword>
	<keyword>burn</keyword>
	<keyword>sedation</keyword>
</DOC>